Multiparametric MRI for Characterization of Hepatocellular Carcinoma

Condition(s) studied

Investigational drug(s) / intervention(s)

Multiparametric MRI: Diagnostic multiparametric liver MRI, performed at three time points: before (≤14 days), 24 hours after, and 4-6 weeks after TACE or 3 months after SIRT.

Study summary

This prospective observational study investigates using multiparametric magnetic resonance imaging (MRI) to improve the characterization and management of therapy for hepatocellular carcinoma (HCC). The goal is to evaluate whether advanced MRI parameters can support noninvasive diagnostic assessments and personalized treatment plans for patients with HCC. The study is being conducted at a single university center in Germany and includes adult patients with confirmed or suspected HCC. Participants will undergo standardized multiparametric MRI examinations, and the imaging data will be correlated with clinical, pathological, and therapeutic outcomes. No study-specific interventions or medications will be administered.

Eligibility

Primary outcome measure(s)

• Correlation of multiparametric MRI parameters with early therapy response — 4 to 6 weeks after TACE, 3 months after SIRT
  Evaluation of mpMRI features (e.g. ADC values, T1 relaxation time, enhancement patterns) in relation to early treatment response assessed 4-6 weeks after TACE or 3 months after SIRT using modified RECIST (mRECIST) criteria

Trial sites (1)

More University Hospital Muenster trials in Germany

Other trials for the same condition